SUMMIT-90 statistically powered phase 2b study to evaluate APEX-90 macrodose synthetic psilocybin in-clinic with assisted psychotherapy VANCOUVER, BC, April 20, 2023 /CNW/ – Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, is pleased to announce approval of SUMMIT-90. SUMMIT-90 is a landmark…


Previous articlePsychedelics Weekly – The Church of Psilomethoxin Controversy, Psychedelics for Long COVID, and The Growth of Bicycle Day
Next articleBetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California